Clinical Trials Browser

Phase 1/2 × Withdrawn × belantamab mafodotin × Clear all

NCT05493618 2023-01-27

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

Phase 1/2 Withdrawn

Multiple Myeloma